Galectin Therapeutics

$2.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-2.18%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GALT and other stocks, options, and ETFs commission-free!

About GALT

Galectin Therapeutics Inc. Common Stock, also called Galectin Therapeutics, is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA. The listed name for GALT is Galectin Therapeutics Inc. Common Stock.

CEO
Joel Lewis
Employees
7
Headquarters
Norcross, Georgia
Founded
2000
Market Cap
128.42M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
358.67K
High Today
$2.29
Low Today
$2.15
Open Price
$2.27
Volume
229.17K
52 Week High
$3.85
52 Week Low
$1.50

GALT Earnings

-$0.14
-$0.09
-$0.05
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

CVE+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure